Symptom Clusters in Children With Exacerbation-prone Asthma

Description

Pediatric participants with exacerbation-prone asthma will receive an intramuscular injection of triamcinolone acetonide and will be followed for 48 weeks. The study visit 2 weeks after the injection will assess the response to the study medication, while the remaining study visits will examine the temporal stability of the symptom clusters.

Conditions

Asthma in Children

Talk to us

Study Overview

On this page

Study Details

Study overview

Pediatric participants with exacerbation-prone asthma will receive an intramuscular injection of triamcinolone acetonide and will be followed for 48 weeks. The study visit 2 weeks after the injection will assess the response to the study medication, while the remaining study visits will examine the temporal stability of the symptom clusters.

Symptom Clusters in Children With Exacerbation-prone Asthma

Symptom Clusters in Children With Exacerbation-prone Asthma

Condition
Asthma in Children
Intervention / Treatment

-

Contacts and Locations

Atlanta

Children's Healthcare of Altanta, Atlanta, Georgia, United States, 30322

Atlanta

Emory Children's Center, Atlanta, Georgia, United States, 30322

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age 6 to less than 21 years at the enrollment visit
  • * Physician diagnosis of asthma
  • * History of an asthma exacerbation in the previous 12 months, defined as either:
  • * Treatment with systemic corticosteroids, or
  • * Increase in rescue medication use (i.e., albuterol or inhaled corticosteroid) for 24 hours or more, or
  • * One or more missed school days due to asthma symptoms, or
  • * An unscheduled visit for asthma at either a physician's office, urgent care, hospital emergency room, or
  • * Hospitalization for asthma
  • * Previous allergic reaction to systemic corticosteroids
  • * Hepatic, biliary, or renal disease that can interfere with drug metabolism/excretion
  • * Chronic medical disorders that may increase the risk of drug-related injury, including osteogenesis imperfecta (increased risk of fracture with corticosteroids), or Crohn's disease, ulcerative colitis, juvenile rheumatoid arthritis, clotting disorders, or Factor deficiency (increased risk of bleeding with corticosteroid therapy)
  • * Pregnancy
  • * Current smoking
  • * Congenital disorders or deformities of the chest wall, lungs or airways
  • * History of premature birth \<35 weeks gestation
  • * Unwillingness to receive triamcinolone
  • * Planning to relocate before study completion

Ages Eligible for Study

6 Years to 21 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Emory University,

Anne Fitzpatrick, PhD, PRINCIPAL_INVESTIGATOR, Emory University

Study Record Dates

2025-07-31